Revised 16 September 2026 · v1.0.0 · what changed

On 9 July 2026, Dr. Reddy's Laboratories called an emergency investor meeting to disclose something no regulator had yet flagged: an impurity in a scale-up validation batch of its own synthetic semaglutide API had pushed the finished injectable out of specification. The company halted commercial API supply to its manufacturing partner, cut its FY27 pen-supply target from 12 million to 6–7 million, and booked a ₹240 crore provision that dragged quarterly net profit down 69% year on year. Nothing about this is a China-dependency story or a pricing story — it is what happens when the process risk in synthesising a complex API at commercial scale, not the economics of buying it from someone else, is the thing that goes wrong.

1. What actually happened

The issue surfaced during scale-up of Dr. Reddy's synthetic semaglutide manufacturing process: a batch produced at the larger, commercial scale showed an impurity that put the finished drug product out of specification. Management was explicit that this was process-related and scale-specific — batches made at the smaller, already-validated scale, including everything already shipped to the market, were not affected, and the company reported no patient-safety impact and no recall. The distinction matters: this was Dr. Reddy's own quality system catching a scale-up problem before it reached patients, not a regulator finding contamination in product already in circulation.

The company paused commercial API supply to OneSource Specialty Pharma, the CDMO (contract development and manufacturing organisation) partner that fills and finishes the injection pens for the India, Canada and other partner markets Dr. Reddy's semaglutide programme covers. OneSource itself said the delay would not materially affect its own earnings, citing a diversified customer base rather than reliance on this single programme — a useful marker that the risk here sits specifically with the API synthesis step, not the downstream fill-finish business.

2. The financial and guidance hit

FY27 pen guidance. Cut 45%, from 12 million to 6–7 million; the revised range spans India, Canada and partner markets combined, with supply targeted from November 2026 onward.

Q1 FY27 one-time provision. ₹240 crore, for inventory write-down and associated costs on the affected API batches.

Q1 FY27 net profit, year on year. Down 69%, with the provision as the primary driver; the underlying base business reportedly still grew.

Share price. Down 3.7% on 10 July, after an intraday fall of up to 5.5% the prior session, trading around ₹1,275 through the disclosure window.

Resumption timeline. Testing was expected to complete around the third week of September 2026, with commercial supply resuming from November — a revision from the initial October estimate given at the 9 July call.

3. The opportunity this delayed

The timing is what makes this costly. Novo Nordisk's semaglutide composition patent expired in India on 20 March 2026, and CDSCO had already cleared a wave of Indian formulations ahead of that date — approvals for weight-management and type-2-diabetes versions ran from September to December 2025, with Zydus Lifesciences, Sun Pharma and Alkem Laboratories among those cleared by January 2026. By the Monday after patent expiry, more than five domestic manufacturers had already launched, several pricing 70–90% below Novo's branded product; more than 40 companies were reported preparing versions. Novo's own India pricing had run ₹10,000–16,000 a month; the cheapest generics launched as low as ₹1,290.

Dr. Reddy's had cleared its own approvals for type-2 diabetes and, via OneSource, for the Canadian market as well (Health Canada approval), and had set a first-year target of 12 million pens before the API issue cut that in half. Against a domestic market of roughly 89 million diabetic adults and a fast-growing obesity-drug segment, and a global GLP-1 opportunity opening as the same patent lapses in over 100 countries, a five-month supply gap is a real, quantifiable piece of market share handed to competitors who didn't have the same scale-up problem — not a rounding error.

4. Why this is the more instructive API story, not just a bad quarter

This blog has already covered India's pharma-API dependency on China as largely a scale-and-pricing problem: Chinese paracetamol API, for instance, has reportedly fallen from around ₹900/kg at pandemic-era highs to around ₹250/kg, pricing a new Indian synthesis plant out of the market even when the chemistry and the feedstock exist domestically. Dr. Reddy's semaglutide episode is a different failure mode entirely — not a Chinese producer underpricing an Indian one, but an Indian producer's own commercial-scale synthesis process failing a specification test that a smaller validation batch had passed. Complex peptide APIs like semaglutide carry exactly this kind of scale-up risk: a process that works cleanly at pilot scale does not automatically work the same way at the volumes a 12-million-pen-a-year launch requires, and finding that out costs months and hundreds of crores even when nothing reaches a patient.

That is a genuine constraint on how fast India's pharma industry can move from formulation strength into API and biologics leadership — a policy outlay can fund a plant and a PLI scheme can subsidise a molecule, but neither substitutes for the process-engineering maturity that catches a scale-up impurity in a validation batch instead of a market recall. Dr. Reddy's disclosure discipline here — an emergency investor call, a self-identified issue, an explicit no-recall statement — is itself evidence the underlying quality system worked as intended, even though the commercial cost was real.

Sources: Dr. Reddy's Laboratories 9 July 2026 investor call and subsequent Form 6-K SEC filing (via StockTitan); Business Standard reporting on the share-price reaction and OneSource's own earnings-impact statement; Investing.com and Sahi.com coverage of Q1 FY27 results, the ₹240cr provision and the revised 6–7 million pen guidance; PIB/CDSCO-adjacent reporting (Business Standard, BusinessToday) on the semaglutide patent-expiry timeline, CDSCO approval dates and generic pricing; this blog's own "India Cannot Sell ‘China-Free’ Medicine While Importing 43% of What's In It" for the paracetamol API price comparison, reused rather than re-derived. Figures on total preparing-to-launch competitor counts and domestic diabetic-population size are as reported in secondary industry coverage, not independently verified against a government dataset.

Related on this blog

See also: India Cannot Sell “China-Free” Medicine While Importing 43% of What's In It · Ethanol Freed Up Refinery Capacity for Petrochemicals. The Pharma Chain Hasn't Seen Much of It Yet..

About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.